Recruiting

Egg Consumption

Sponsor:

University of Kansas Medical Center

Code:

NCT07583186

Conditions

Pregnancy Related

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Interventions

Egg Supplementation

Healthy Prenatal Diet

Study Details

Brief summary:

The fetal brain requires DHA, choline, lutein, and zeaxanthin (L/Z) for development, dependent on maternal intake during pregnancy. However, many pregnant women do not meet daily requirements through diet or prenatal vitamins. Egg yolks are rich in choline, and women who consume eggs daily are more likely to meet the adequate intake of 450 mg/day. A recent study by Christifano et al. found that maternal egg and neuroprotective nutrient intake predicted neurodevelopment at 32 and 36 weeks of gestation. This study aims to determine if fetal neurodevelopment is enhanced among women who consume a prenatal diet emphasizing egg consumption (EGG) versus a healthy prenatal diet education control group (HPD). Women between 12-20 weeks' gestation will be randomized into EGG and HPD groups. The EGG group will receive education on the importance of prenatal choline and egg consumption and be encouraged to consume 10-14 eggs per week. The HPD group will receive education on a healthy prenatal diet. Both groups will be encouraged to take a DHA supplement, and dietary intake of choline, L/Z, and DHA will be collected. Fetal heart rate variability will be measured at 36 weeks gestation and infant EEGs will be conducted postnatally to examine brain function. Increasing prenatal egg consumption is both economical and feasible to boost prenatal choline intake, promote offspring neurodevelopment, and guide prenatal dietary recommendations.

Conditions

Pregnancy Related

Study ID

NCT07583186

Start date

Jan 1, 2026

Status verified date

Oct, 2025

Completion date

Jun, 2028

Anticipated

Primary completion date

Jun, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Pregnant females ≥18 years of age
  • 12 to 20-weeks' gestation at enrollment
  • No serious illnesses likely to confound study outcomes
  • Consuming 3 eggs/week or less at enrollment and willing to increase consumption during the study
  • Singleton gestation
  • Available by telephone and text

Exclusion Criteria:

  • Less than 18 years at enrollment
  • Gestational age at enrollment <12 or >20 weeks
  • Any serious illness likely to confound study outcomes
  • Consuming more than 3 eggs per week at enrollment
  • Unable/unwilling to consume eggs until delivery or egg allergy
  • Expecting multiple infants
  • No access to telephone or text

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: EGG Group

The EGG group will receive education on the importance of prenatal choline and egg consumption and be encouraged to consume 10-14 eggs per week.

placebo comparator: HPD Group

The HPD group will receive education on a healthy prenatal diet

Interventions

Egg Supplementation

Encouraged to consume 10-14 eggs per week.

Healthy Prenatal Diet

Educated on standard healthy prenatal diet and encouraged to follow recommendations.

Primary outcome measure

  • Fetal neurodevelopment as indexed by heart rate variability (HRV) [ Time Frame: 36 weeks gestational age ]

Central Contacts and Locations

Central contacts

Locations

The University of Kansas Medical Center

Recruiting

Kansas City, Kansas, United States, 66160

Contacts

Nicole Mathis, MS

913-588-1906

Lara Bennett, MS

913-945-9149

Principal Investigator:

Danielle Christifano, PhD

More Information

Sponsor

University of Kansas Medical Center

Last update posted

May 13, 2026

Last verified

Oct, 2025

Keywords

  • Pregnancy
  • Prenatal Nutrition
  • Neurodevelopment

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Kansas Medical Center on 2026-05-13.